Should I change the topical antibiotic from erythromycin to a broad‑spectrum fluoroquinolone for a patient with a large corneal abrasion who now has blurred vision and fluorescein staining showing corneal and peri‑ocular uptake?

Switch to Fluoroquinolone Immediately

Yes, you need to switch from erythromycin to a broad-spectrum fluoroquinolone immediately. The persistent fluorescein uptake on both the cornea and peri-ocular tissue, combined with ongoing blurred vision, indicates either inadequate treatment of a large corneal abrasion or progression to bacterial keratitis—both scenarios where erythromycin is inappropriate.

Critical Clinical Context

Your patient has several red flags:

• Large corneal abrasion (high-risk for infection)
• Persistent fluorescein staining (failure to heal or progression)
• Peri-ocular uptake (suggests conjunctival involvement or epithelial toxicity)
• Ongoing blurred vision (indicates significant corneal pathology)

The FDA label for topical erythromycin explicitly states it is "for topical use only; not for ophthalmic use" 1. You are using a dermatologic formulation designed for acne treatment 1, which contains 71.5% alcohol 1—this vehicle is toxic to ocular tissues and likely contributing to the persistent epithelial defect and peri-ocular uptake you're observing.

Why Erythromycin Failed Here

• Erythromycin ointment formulations lack adequate corneal penetration due to poor solubility 2
• The topical dermatologic preparation contains alcohol and is contraindicated for ocular use 1
• For large corneal abrasions, ointments may be useful only "at bedtime in less severe cases" 2—your patient has a large abrasion requiring more aggressive therapy

Recommended Switch

Prescribe a fluoroquinolone immediately:

First-line options (FDA-approved for bacterial keratitis):

• Levofloxacin 1.5% drops every 2 hours while awake for 48 hours, then QID 2
• Ciprofloxacin 0.3% or Ofloxacin 0.3% with similar dosing 2

Alternative (better gram-positive coverage, though not FDA-approved for keratitis):

• Moxifloxacin 0.5% or Gatifloxacin 0.5% 2—these fourth-generation fluoroquinolones showed superior healing times in network meta-analysis, with moxifloxacin demonstrating 6.81 days faster healing compared to ciprofloxacin 3

Clinical Reasoning

The 2024 Bacterial Keratitis Preferred Practice Pattern guidelines emphasize that single-drug fluoroquinolone therapy is as effective as fortified combination therapy for most cases 2. For large corneal abrasions or suspected bacterial keratitis:

• Fluoroquinolones achieve high tissue levels and adequate corneal penetration 2
• They provide broad-spectrum coverage against common pathogens
• Recent meta-analysis confirms fluoroquinolones have equivalent cure rates to fortified antibiotics but shorter time to cure 4
• Network meta-analysis ranks moxifloxacin (SUCRA 83.1) and vancomycin + ceftazidime (SUCRA 83.8) as most effective 3

Critical Next Steps

1. Discontinue erythromycin immediately
2. Start fluoroquinolone drops (not ointment for initial therapy)
3. Re-examine in 24 hours to assess:
   • Reduction in epithelial defect size
   • Decreased fluorescein uptake
   • Improvement in symptoms
4. If no improvement in 48 hours, consider:
   • Fortified antibiotics (vancomycin + ceftazidime or cefazolin + tobramycin) 2
   • Culture and sensitivity testing
   • Ophthalmology referral

Common Pitfalls to Avoid

• Don't patch the eye—increases risk of bacterial keratitis 2
• Don't use topical NSAIDs routinely—while they reduce pain, evidence for corneal abrasions is limited 5
• Don't delay switching antibiotics—the guideline states therapy should be modified "when the eye shows a lack of improvement or stabilization within 48 hours" 2, and you're already beyond that window
• Watch for fluoroquinolone toxicity—prolonged use can cause epithelial toxicity and crystalline deposits 6, but this is a concern with chronic unsupervised use, not initial appropriate therapy

The persistent fluorescein uptake despite treatment suggests either drug toxicity from the inappropriate erythromycin formulation or progression to infection. Either scenario mandates immediate switch to appropriate ophthalmic fluoroquinolone therapy.